vTv Therapeutics Inc. (VTVT)
NASDAQ: VTVT · Real-Time Price · USD
13.60
-0.07 (-0.48%)
Nov 7, 2024, 4:00 PM EST - Market closed

Company Description

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases.

The company’s lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.

It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention.

In addition, the company’s other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2–related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions.

vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S.

The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Group LLC.

vTv Therapeutics Inc.
vTv Therapeutics logo
Country United States
Founded 2015
IPO Date Jul 30, 2015
Industry Biotechnology
Sector Healthcare
Employees 16
CEO Paul Sekhri

Contact Details

Address:
3980 Premier Drive, Suite 310
High Point, North Carolina 27265
United States
Phone 336 841 0300
Website vtvtherapeutics.com

Stock Details

Ticker Symbol VTVT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001641489
CUSIP Number 918385105
ISIN Number US9183852048
Employer ID 47-3916571
SIC Code 2834

Key Executives

Name Position
Paul J. Sekhri M.Sc. Chief Executive Officer, President and Chairman of the Board
Steven Tuch M.B.A. Executive Vice President and Chief Financial Officer
Dr. Carmen Valcarce Ph.D. Chief Scientific Officer and Executive Vice President
Elizabeth M. Keiley Executive Vice President and General Counsel
Richard S. Nelson Executive Vice President of Corporate Development and Director
Dr. Thomas Strack M.D., Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Oct 25, 2024 8-K Current Report
Sep 23, 2024 S-8 Securities to be offered to employees in employee benefit plans
Aug 8, 2024 8-K Current Report
Aug 8, 2024 10-Q Quarterly Report
Jul 26, 2024 8-K Current Report
Jul 2, 2024 8-K Current Report
Jun 14, 2024 8-K Current Report
May 9, 2024 10-Q Quarterly Report
May 9, 2024 8-K Current Report
Apr 29, 2024 EFFECT Notice of Effectiveness